I-131 Blood Dosimetry in Thyroid Cancer Therapy

Introduction

Blood-based dosimetry converts an I-131 thyroid cancer prescription from a fixed number into a patient-specific calculation: it finds the largest activity that keeps the absorbed dose to the blood at or below roughly 2 Gy and the 48-hour whole-body retention within established limits. The blood dose is used as a practical surrogate for the dose to the red bone marrow, the organ most likely to limit how much I-131 a patient can safely receive. ^{1, 2}

Radioiodine (I-131) remains a cornerstone of therapy for differentiated thyroid cancer (DTC), especially for distant metastatic disease. The therapeutic question is deceptively simple: how much activity should the patient receive? Two philosophies answer it differently. Fixed, or empiric, activity prescribes a standard amount — for example, a set number of millicuries for remnant ablation or for metastatic disease — independent of how the individual patient handles the iodine. Dosimetry-guided therapy instead measures the patient's own uptake, retention, and clearance, then solves for the activity that reaches a defined safety limit. ^{1, 3}

Blood-based dosimetry, often called the Benua-Leeper method after the group that developed it at Memorial Sloan Kettering in the 1960s, is the oldest and most widely used dosimetric approach. It rests on a single organizing idea: the red marrow is usually the dose-limiting normal tissue, and the circulating blood is a measurable, accessible surrogate for marrow dose. By capping the blood dose, the method lets a patient receive the most effective activity the marrow can tolerate instead of an arbitrary fixed dose that may be too small to control disease or large enough to cause avoidable toxicity. ^{1, 2}

This article explains the physics behind blood-based dosimetry, the measurements it requires, the dose and retention limits that constrain the prescription, and how the calculation fits into a defensible, regulation-aligned therapy program. DRPS supports nuclear medicine and theranostics programs with PET/CT and nuclear medicine physics and medical physics consulting across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What blood-based dosimetry is trying to protect

The goal of blood-based dosimetry is to protect the red bone marrow — and, when lung metastases are present, the lungs — while delivering the highest practical tumor dose. In most patients receiving I-131 for thyroid cancer, the first normal tissue to show dose-related injury is the hematopoietic marrow. Because sampling marrow directly is impractical, the circulating blood is used as a surrogate: it bathes the marrow, it carries the penetrating photon dose from activity distributed throughout the body, and it can be sampled serially with ordinary venipuncture. ^{1, 2}

The Benua-Leeper framework translates this into planning constraints. The classic limits are:

• an absorbed dose to blood of no more than about 2 Gy (200 rad), the widely accepted ceiling for avoiding significant marrow toxicity; ²
• whole-body retention at 48 hours of no more than about 4.44 GBq (120 mCi); and
• whole-body retention at 48 hours of no more than about 2.96 GBq (80 mCi) in the presence of diffuse, iodine-avid lung metastases, to reduce the risk of radiation pneumonitis and pulmonary fibrosis. ^{2, 4}

Whichever constraint is reached first sets the maximum activity for that patient. For a patient with fast iodine clearance, the blood dose limit usually governs; for a patient who retains iodine (for example, with impaired renal function), the 48-hour retention limit can bind first. ^{1, 2, 4}

Why the marrow, and why blood as its stand-in

Red marrow is radiosensitive, it is distributed throughout the skeleton, and its dose from I-131 comes from two routes: the short-range beta particles emitted by activity physically present in the blood that perfuses the marrow space, and the penetrating 364 keV gamma photons emitted by activity distributed across the whole body. Blood sampling captures the first route directly and, combined with whole-body retention measurements, lets the physicist estimate the second. This two-component structure — a local (self) contribution plus a whole-body (remainder) contribution — is the heart of the calculation. ^{1, 2}

For the biokinetic background that feeds these calculations, see our overview of radiopharmaceutical dosimetry and ICRP 128 and the MIRD schema for internal dosimetry.

Key Technical Principles

The MIRD framework

Internal absorbed dose in nuclear medicine follows the Medical Internal Radiation Dose (MIRD) schema. The absorbed dose $D$ to a target region is the product of the time-integrated activity (cumulated activity) $\tilde{A}$ in each source region and an $S$ value that captures the physics of energy deposition from source to target:

$$D=\sum _S{\tilde{A}}_S\cdot S(T\leftarrow S)$$

The cumulated activity is the area under the time-activity curve — it is why the method requires serial measurements rather than a single snapshot:

$$\tilde{A}={\int }_0^{\infty }A(t)dt$$

For a compartment that clears mono-exponentially, this integral reduces to the activity at a reference time divided by the effective decay constant, which is why the effective half-life is the single most important biokinetic parameter in the calculation.

Physical, biological, and effective half-life

Activity leaves a compartment both by radioactive decay and by biological clearance. The two act together, so the effective half-life is always shorter than either the physical or the biological half-life:

$$\frac{1}{T_{1/2,\text{eff}}}=\frac{1}{T_{1/2,\text{phys}}}+\frac{1}{T_{1/2,\text{bio}}}$$

For I-131, the physical half-life is $T_{1/2,\text{phys}}=8.02\text{d}$. The corresponding decay constant used in the retention equations is:

$${\lambda }_{\text{eff}}=\frac{\ln 2}{T_{1/2,\text{eff}}}$$

Whole-body retention after administration of activity $A_0$ then follows:

$$R(t)=A_0{e}^{-{\lambda }_{\text{eff}}t}$$

The two-component blood dose

The absorbed dose to blood per unit administered activity is modeled as the sum of a self-irradiation term, from beta and non-penetrating emissions of activity in the blood itself, and a whole-body (remainder) term, from penetrating photons emitted by activity distributed throughout the body:

$${\left(\frac{D}{A_0}\right)}_{\text{blood}}={\left(\frac{D}{A_0}\right)}_{\beta ,\text{blood}}+{\left(\frac{D}{A_0}\right)}_{\gamma ,\text{whole body}}$$

The first term is driven by the integral of the measured blood activity concentration; the second by the integral of whole-body retention and the patient's body mass. Standardized operational procedures for computing both terms are published by the EANM Dosimetry Committee, which also codifies the 2 Gy blood limit. ²

Comparison: dosimetry-guided versus fixed-activity therapy

The table contrasts the general approaches; the specific limits and whether dosimetry is used should follow the authorized user's judgment, applicable guidelines, and the facility's protocol. ^{1, 3}

Worked example: when the retention limit binds

Consider a patient whose tracer study (a small diagnostic activity of I-131 followed by serial whole-body counting) yields a whole-body effective half-life of $T_{1/2,\text{eff}}=2.0\text{d}$, reflecting relatively slow clearance. The fraction of administered activity retained in the whole body at 48 hours is:

$$\frac{R(48\text{h})}{A_0}=e^{-{\lambda }_{\text{eff}}t}=e^{-\frac{\ln 2}{2.0\text{d}}\times 2.0\text{d}}=e^{-\ln 2}=0.50$$

To satisfy the 48-hour whole-body retention limit of 4.44 GBq (120 mCi), the maximum administered activity is:

$$A_{0,\text{max}}=\frac{4.44\text{GBq}}{0.50}=8.9\text{GBq}\approx 240\text{mCi}$$

If the same patient has diffuse iodine-avid lung metastases, the tighter 2.96 GBq (80 mCi) limit applies:

$$A_{0,\text{max}}=\frac{2.96\text{GBq}}{0.50}=5.9\text{GBq}\approx 160\text{mCi}$$

In parallel, the physicist computes the blood dose per unit activity from the blood and whole-body curves and checks the 2 Gy ceiling. The prescribed activity is the smallest value that satisfies every binding constraint. For a patient with fast clearance — say an effective half-life of only 10–16 hours — the retention fraction at 48 hours is far below 0.5, the retention limit is not binding, and the 2 Gy blood dose limit governs instead. ^{2, 4}

Clinical Impact

Matching activity to the patient

The clinical value of blood-based dosimetry is that it individualizes the therapeutic activity to the patient's own biology rather than a population average. Patients clear iodine at very different rates. Renal function, hydration, thyroid-stimulating hormone preparation (thyroid hormone withdrawal versus recombinant human TSH), prior therapies, and tumor burden all change the time-activity curves. A fixed activity that is safe for a fast clearer may deliver an excessive marrow or lung dose to a slow clearer, and an activity that is safe for a slow clearer may be too small to control disease in a fast clearer. ^{1, 3}

Dosimetry-guided treatment can allow substantially higher — but still safe — activities than empiric dosing when the marrow can tolerate them. In one widely cited retrospective series, dosimetry using marrow dose limits permitted administered activities as high as 38.5 GBq (about 1040 mCi) in selected patients, with no permanent marrow suppression observed when the red marrow dose stayed below the chosen limit. ³

Protecting the lungs

Diffuse, iodine-avid pulmonary metastases are the classic reason the 80 mCi retention limit exists. When many micrometastases concentrate iodine and the lungs retain activity, the cumulative lung dose can rise to levels associated with radiation pneumonitis and, later, pulmonary fibrosis. The 2.96 GBq (80 mCi) 48-hour whole-body retention limit is a pragmatic surrogate derived from clinical experience; detailed analyses using patient-specific imaging-based dosimetry show that the actual tolerable activity depends on the true lung retention and distribution, which is why imaging-based methods are an area of continued refinement. ⁴

Reproducibility and the limits of the model

Different published formulations of blood and red-marrow dosimetry do not all give the same number for the same patient. A comparison of several mathematical models reported average differences of roughly 20% between the Benua formulation and alternatives, underscoring that the calculated "dose" depends on the chosen model and assumptions. ⁵ This is a reason to standardize the method within a program, document the formulation used, and interpret the result as a defensible planning estimate rather than an exact biological dose. For the broader principles of quantitative accuracy in nuclear medicine, see quantitative SPECT/CT calibration.

Practical Optimization Tips

A defensible blood-based dosimetry workflow generally follows the same sequence.

1. Administer a tracer and schedule sampling

Give a small, known tracer activity of I-131 and plan serial collections over several days (commonly spanning roughly 2 hours out to about 96–120 hours), long enough to characterize the clearance and extrapolate the tails of the curves. ²

2. Collect paired blood and whole-body data

At each time point, draw a blood sample (for the blood activity concentration) and measure whole-body retention by external counting (for example, a fixed-geometry probe or gamma camera with a reproducible patient-to-detector distance). Consistent geometry is essential, because the whole-body term depends on reliable retention ratios, not absolute counts alone. ²

3. Fit the time-activity curves and integrate

Fit the blood and whole-body data to appropriate functions, extrapolate to infinity, and compute the cumulated activities. These integrals feed both components of the blood dose. ^{1, 2}

4. Compute dose per unit activity and apply the limits

Calculate blood dose per unit administered activity and whole-body retention per unit administered activity, then solve for the largest $A_0$ that satisfies the 2 Gy blood limit and the 48-hour retention limits (using the 80 mCi lung limit when diffuse pulmonary metastases are present). ^{2, 4}

5. Document and reconcile with clinical judgment

Record the measurement protocol, the fitted parameters, the model used, and the resulting maximum safe activity. Provide the result to the authorized user, who integrates it with tumor dose considerations, patient factors, and the written directive. ⁶

Common pitfalls to avoid

• Too few or too-short time points. Missing the tail of the curve biases the cumulated activity and the dose estimate.
• Inconsistent counting geometry. Variable patient-to-detector distance corrupts the whole-body retention term.
• Ignoring the lung limit. In diffuse pulmonary metastatic disease, the 80 mCi retention limit can be the binding constraint. ⁴
• Treating the calculated dose as exact. Model choice changes the number; standardize and document the method. ⁵
• Decoupling dosimetry from the written directive. The calculation informs, but the authorized user's directive governs the administration. ⁶

Regulatory Considerations

I-131 therapy for thyroid cancer is a medical use of byproduct material and must comply with the facility's radioactive material license and the federal or Agreement State rules that govern therapy administrations. The dosimetry calculation is a physics input to the prescription; the administration itself is tightly regulated.

Key frameworks to reference:

• 10 CFR Part 35 — Medical Use of Byproduct Material. Therapeutic administrations of unsealed byproduct material require a written directive signed by an authorized user, and the licensee must have procedures to ensure the administration matches the directive. The therapy must be performed under an authorized user and consistent with the license. ⁶
• 10 CFR Part 20 — Standards for Protection Against Radiation. Occupational and public dose limits, posting, and survey requirements apply to the therapy environment and to any inpatient stay. ⁷
• Patient release — 10 CFR 35.75 and Regulatory Guide 8.39. A patient may be released when the total effective dose equivalent to any other individual is not likely to exceed 5 mSv (0.5 rem); written instructions are required when that dose could exceed 1 mSv (0.1 rem), including breastfeeding guidance where relevant. ⁸

Guideline bodies also inform practice. The SNMMI practice guideline for therapy of thyroid disease with I-131 and professional management guidelines describe when dosimetry is appropriate and how therapy should be documented and followed. ⁹ For the inpatient and release side of high-activity therapy, see inpatient I-131 therapy radiation safety and patient release after radiopharmaceutical therapy. The written-directive and recordkeeping requirements are covered in written directives in nuclear medicine.

Of the states DRPS serves, Florida, Maryland, Virginia, California, and Nevada are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC is regulated directly by the NRC. Confirm which authority issues the license and which requirements apply before relying on any dosimetry-based prescription. ^{6, 7}

Frequently Asked Questions (FAQs)

What is blood-based I-131 dosimetry?

Blood-based dosimetry is a pre-therapy calculation that estimates the absorbed dose to the blood (used as a surrogate for red bone marrow) per unit of administered I-131 activity. It lets the team find the largest activity that keeps the blood dose at or below about 2 Gy, which is the widely accepted limit for avoiding marrow toxicity in differentiated thyroid cancer therapy.

Why is 2 Gy used as the blood dose limit?

The 2 Gy limit to blood comes from the Benua-Leeper experience and later series, where blood doses at or below 2 Gy were associated with acceptable, usually transient, hematologic effects. It is a planning constraint, not a biological threshold, and some centers use blood or red-marrow limits with additional conditions.

What are the 120 mCi and 80 mCi retention limits?

In addition to the blood dose limit, the classic method limits whole-body retention at 48 hours to about 4.44 GBq (120 mCi), and to about 2.96 GBq (80 mCi) when diffuse iodine-avid lung metastases are present, to reduce the risk of radiation pneumonitis and pulmonary fibrosis.

How is blood-based dosimetry different from fixed-activity therapy?

Fixed-activity therapy administers a standard activity (for example, a set number of millicuries) regardless of how fast the patient clears iodine. Blood-based dosimetry measures the patient's own retention and clearance and solves for the activity that reaches a dose limit, so slow clearers receive less and fast clearers can safely receive more.

What measurements does the method require?

The patient receives a small tracer activity of I-131, then blood samples and whole-body retention (external counting) are collected at several time points over several days. These data give the blood and whole-body time-activity curves, from which cumulated activity and absorbed dose per unit administered activity are calculated.

Does blood-based dosimetry replace clinical judgment?

No. Dosimetry informs the prescription but does not replace the authorized user's clinical judgment, the written directive, tumor and lung uptake considerations, or patient-specific factors such as renal function and prior therapy. It is one defensible input into a risk-adapted decision.

Who performs and oversees I-131 dosimetry?

A qualified medical physicist typically designs the measurement protocol, performs the calculations, and documents the result, working with the authorized user (physician) who signs the written directive. The radiation safety officer ensures the therapy and patient release comply with the facility's license and NRC or Agreement State rules.

Key Takeaways

• The marrow is usually the dose-limiting tissue, and blood is its measurable surrogate. Blood-based dosimetry caps the blood dose at about 2 Gy to protect the marrow. ²
• Two retention limits protect the whole body and lungs. Whole-body retention at 48 hours is limited to about 4.44 GBq (120 mCi), and to about 2.96 GBq (80 mCi) with diffuse lung metastases. ^{2, 4}
• The binding constraint depends on clearance. Fast clearers are usually limited by the blood dose; slow clearers can be limited by the retention limits.
• Dosimetry individualizes the activity. It can permit higher, still-safe activities in selected patients and avoids overdosing slow clearers. ³
• The calculated dose is model-dependent. Different formulations can differ by roughly 20%; standardize and document the method. ⁵
• Regulation governs the administration. A written directive, Part 20 protections, and patient-release criteria under 10 CFR 35.75 all apply. ^{6, 7, 8}

Conclusion

Blood-based dosimetry is not about chasing a perfect number. It is about making the I-131 prescription a calculated, defensible decision rather than a reflex. By using the circulating blood as a surrogate for the red marrow, measuring the patient's own clearance, and respecting the blood dose and retention limits, the method lets the care team deliver the most effective activity the patient can safely tolerate.

For most remnant-ablation cases, empiric activity remains reasonable and common. But for advanced, metastatic, or biologically unusual disease — especially where high intended activities, altered clearance, or diffuse lung metastases are in play — blood-based dosimetry turns a guess into an informed plan. Done well, it protects the marrow and lungs, documents the rationale, and supports a therapy program that can defend its decisions during clinical review or inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and theranostics programs build and document defensible dosimetry workflows. That can include designing blood and whole-body measurement protocols, performing and independently checking dose calculations, standardizing the chosen model, and aligning the therapy with written-directive, survey, and patient-release requirements through PET/CT and nuclear medicine physics, medical physics consulting, and radiation safety officer support.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong therapy program makes the safe, documented path the easy path for the clinical team.

Related Resources

• I-131 therapy for thyroid cancer
• I-131 hyperthyroidism therapy and dosimetry
• Radioiodine whole-body scintigraphy and SPECT/CT
• The MIRD schema for internal dosimetry
• Radiopharmaceutical dosimetry and ICRP 128
• Inpatient I-131 therapy radiation safety
• PET/CT and nuclear medicine physics
• Medical physics consulting

References

1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171-182. PubMed
2. Lassmann M, Hänscheid H, Chiesa C, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405-1412. doi:10.1007/s00259-008-0761-x. doi.org
3. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44(3):451-456. PubMed
4. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47(12):1985-1994. PubMed
5. Miranti A, Giostra A, Richetta E, Gino E, Pellerito RE, Stasi M. Comparison of mathematical models for red marrow and blood absorbed dose estimation in the radioiodine treatment of advanced differentiated thyroid carcinoma. Phys Med Biol. 2015;60(3):1141-1157. doi:10.1088/0031-9155/60/3/1141. doi.org
6. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
7. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
8. U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. Revision 0, 1997. nrc.gov
9. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-1651. doi:10.2967/jnumed.112.105148. doi.org
10. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020. doi.org